References 1 Group EBTC . Tamoxifen for early breast cancer: an overview of the randomized trials . Lancet 1998 ; 351 : 1451 – 1467 . 2 Report from the Breast Cancer Trials Committee SCTO, Edinburgh . Adjuvant tamoxifen
Search Results
Jennifer A. Ligibel and Eric P. Winer
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
predictive factors? Can certain subsets of premenopausal women with ER-positive tumors be adequately treated using tamoxifen and/or ovarian suppression and forego adjuvant chemotherapy? What is the optimal strategy for using aromatase inhibitors (AIs) in the
Therese B. Bevers
– 5687 . 2. Lamb CA Helguero LA Fabris V . Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma . Breast Cancer Res Treat 2003 ; 79 : 25 – 35 . 3. Sporn MB Dowsett SA Mershon J Bryant HU
Alyssa G. Rieber and Richard L. Theriault
carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases . Lancet 1896 ; 2 : 104 – 107 . 2 Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: report of the National Surgical
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
anthracyclines or trastuzumab; 21 – 23 kidney dysfunction and capecitabine; 16 preexisting neuropathy and taxanes; 24 history of thromboembolism and tamoxifen (venous thromboembolism) or bevacizumab (arterial thromboembolism); 25 , 26 and osteoporosis and
Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster
). BCPT randomized women to receive tamoxifen or placebo, and results showed that the tamoxifen arm had a significant reduction in the risk of developing an estrogen receptor (ER)–positive tumor (relative risk [RR], 0.38; 95% CI, 0.28–0.50), and had no
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
). Patients who received tamoxifen or with depression/anxiety were more likely to develop persistent benzodiazepine use at 3 months (OR, 1.93 [95% CI, 1.12–3.33] and 1.74 [CI, 1.01–3.01], respectively). The other subgroup consisted primarily of clonazepam and
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak
, United Kingdom: Blackwell Healthcare Communications; 1997:22–55. b Eastell R, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone density and bone turnover: results of the ‘Arimidex’ (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study
William Gradishar and Kilian E. Salerno
recent trial data. For premenopausal women at diagnosis, the NCCN Guidelines for Breast Cancer suggest tamoxifen for 5 years, with or without ovarian suppression, or an AI for 5 years combined with ovarian suppression or ablation (category 1). Women who
John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner, and Liliana E. Pezzin
studying the relationship between pharmaceutical plan characteristics and choice of therapy. For most postmenopausal women with hormone receptor–positive (HR+) disease there are essentially 2 options for oral endocrine therapy: tamoxifen, whose efficacy was
